Malladi Drugs And Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 70.00 Cr
- Paid Up Capital ₹ 63.93 Cr
- Company Age 44 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 583.60 Cr
- Satisfied Charges ₹ 598.20 Cr
- Revenue Growth 23.19%
- Profit Growth 123.25%
- Ebitda 20.37%
- Net Worth 59.05%
- Total Assets 17.50%
About Malladi Drugs And Pharmaceuticals
Malladi Drugs And Pharmaceuticals Limited (MDAPL) is a leading Public Limited Indian Non-Government Company incorporated in India on 21 August 1980 and has a history of 44 years and five months. Its registered office is in Chennai, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 70.00 Cr and a paid-up capital of Rs 63.93 Cr.
The company currently has active open charges totaling ₹583.60 Cr. The company has closed loans amounting to ₹598.20 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Malladi Drugs And Pharmaceuticals Limited India are Sandip Neogi as CFO and Karthik Kanagasabesan as Company Secretary. Subramanian Vasudevan, Prashant Malladi, Shreya Sistla, and Six other members serve as directors at the Company.
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24230TN1980PLC008382
- Company No.
008382
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
21 Aug 1980
- Date of AGM
31 Jul 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
What products or services does Malladi Drugs And Pharmaceuticals Limited offer?
Malladi Drugs And Pharmaceuticals Limited offers a wide range of products and services, including Brain & Nervous System Drugs, Antidepressant & Anti Anxiety Medicines, TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Cardiovascular Drugs & Medication, Blood Pressure Medicine, Common Disease Medicines, Nasal Drops, Sexual Wellness Products, Contraceptives.
Who are the key members and board of directors at Malladi Drugs And Pharmaceuticals?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shreya Sistla  | Managing Director | 02-Dec-1998 | Current |
| Sandip Neogi | CFO | 06-Oct-2023 | Current |
| Karthik Kanagasabesan | Company Secretary | 06-Apr-2022 | Current |
Board Members (8)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Venganelloor Narayanaswami | Whole-Time Director | 12-May-2011 | Current |
| Prashant Malladi | Whole-Time Director | 03-Sep-2011 | Current |
| Subramanian Vasudevan | Nominee Director | 28-Mar-2022 | Current |
| Revathi Raghunathan | Additional Director | 27-Aug-2024 | Current |
| Tirunelveli Devarajan | Nominee Director | 28-Mar-2022 | Current |
| Hariharan Sivaramakrishnan | Director | 29-Aug-2023 | Current |
Financial Performance of Malladi Drugs And Pharmaceuticals.
Malladi Drugs And Pharmaceuticals Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 23.19% increase. The company also saw a substantial improvement in profitability, with a 123.25% increase in profit. The company's net worth Soared by an impressive increase of 59.05%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Malladi Drugs And Pharmaceuticals?
In 2022, Malladi Drugs And Pharmaceuticals had a promoter holding of 16.35% and a public holding of 83.65%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
_LIMITED.webp)
W.S. Industries (India) LimitedRevathi Raghunathan is a mutual person
Alniche Lifesciences Private LimitedTirunelveli Devarajan is a mutual person
Ankura Medical & Research Centre Private LimitedTirunelveli Devarajan is a mutual person
Veranda Learning Solutions LimitedRevathi Raghunathan is a mutual person
Rajasthan Explosives And Chemicals LimitedDilip Patel is a mutual person
Phasorz Technologies Private LimitedTirunelveli Devarajan is a mutual person
Charges (Loans)
₹583.60 Cr
₹598.20 Cr
Charges Breakdown by Lending Institutions
- Others : 432.27 Cr
- Axis Bank Limited : 83.45 Cr
- Hdfc Bank Limited : 67.70 Cr
- First Leasing Co Of India Limited : 0.18 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Jun 2023 | Hdfc Bank Limited | ₹67.70 Cr | Open |
| 18 Mar 2023 | Axis Bank Limited | ₹6.50 Cr | Open |
| 27 Jan 2023 | Others | ₹105.00 Cr | Open |
| 20 Dec 2022 | Others | ₹10.00 Cr | Open |
| 15 Nov 2022 | Axis Bank Limited | ₹76.95 Cr | Open |
How Many Employees Work at Malladi Drugs And Pharmaceuticals?
Malladi Drugs And Pharmaceuticals has a workforce of 832 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Malladi Drugs And Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Malladi Drugs And Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
